Short answer
Arcus Biosciences, Inc. (RCUS) filed an 8-K current report with the SEC on October 21, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Preliminary liquidity of approximately $694.0 million in cash, equivalents and marketable securities as of September 30, 2026.
Arcus Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Preliminary liquidity of approximately $694.0 million in cash, equivalents and marketable securities as of September 30, 2026
- Balance supports ongoing clinical development and operations, but runway cannot be assessed without burn-rate and expense data
- Estimate remains unaudited and subject to financial-close adjustments, limiting confidence in the reported balance
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcus Biosciences, Inc. 8-K filings
Get the next RCUS 8-K as it lands
Follow RCUS for push alerts, or ask the research agent what this filing means.